TrialBlood advances2025

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma.

Alexey V Danilov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.